Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) shares were up 3.7% during trading on Thursday . The company traded as high as $153.89 and last traded at $153.89, with a volume of 274,630 shares trading hands. The stock had previously closed at $148.34.

Several research analysts recently weighed in on ICPT shares. Vetr cut Intercept Pharmaceuticals from a “hold” rating to a “sell” rating and set a $147.31 target price for the company. in a research note on Monday, April 18th. Goldman Sachs Group Inc. started coverage on Intercept Pharmaceuticals in a research note on Wednesday, March 30th. They set a “neutral” rating and a $114.00 target price for the company. Wells Fargo & Co. raised Intercept Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Tuesday, April 5th. Morgan Stanley reaffirmed an “equal weight” rating and set a $100.00 target price on shares of Intercept Pharmaceuticals in a research note on Friday, April 1st. Finally, Robert W. Baird reaffirmed a “buy” rating and set a $32.00 target price on shares of Intercept Pharmaceuticals in a research note on Tuesday, April 5th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $203.08.

The firm has a 50 day moving average price of $148.72 and a 200-day moving average price of $134.04. The stock’s market capitalization is $3.89 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($5.17) EPS for the quarter, missing analysts’ consensus estimates of ($3.60) by $1.57. During the same quarter last year, the company posted ($1.78) earnings per share. On average, analysts anticipate that Intercept Pharmaceuticals Inc. will post ($16.82) earnings per share for the current fiscal year.

In related news, CEO Mark Pruzanski sold 714 shares of the company’s stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $145.11, for a total value of $103,608.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Lisa Bright sold 251 shares of the company’s stock in a transaction dated Wednesday, May 25th. The shares were sold at an average price of $137.50, for a total value of $34,512.50. Following the completion of the sale, the insider now owns 18,855 shares of the company’s stock, valued at approximately $2,592,562.50. The disclosure for this sale can be found here.

A number of large investors recently added to or reduced their stakes in ICPT. Rhumbline Advisers increased its stake in Intercept Pharmaceuticals by 0.7% in the fourth quarter. Rhumbline Advisers now owns 15,849 shares of the biopharmaceutical company’s stock worth $2,367,000 after buying an additional 109 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Intercept Pharmaceuticals by 1.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 36,610 shares of the biopharmaceutical company’s stock worth $5,468,000 after buying an additional 578 shares in the last quarter. New York State Common Retirement Fund increased its stake in Intercept Pharmaceuticals by 2.2% in the fourth quarter. New York State Common Retirement Fund now owns 37,400 shares of the biopharmaceutical company’s stock worth $5,586,000 after buying an additional 800 shares in the last quarter. Finally, BB Biotech AG increased its stake in Intercept Pharmaceuticals by 21.4% in the fourth quarter. BB Biotech AG now owns 255,719 shares of the biopharmaceutical company’s stock worth $38,192,000 after buying an additional 45,000 shares in the last quarter.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.